• Venue Hilton Woburn Boston, MA, USA
  • Dates November 13-15, 2024
  • Call +1-815-595-8049

Contact Us

Speakers

Gary R. Matyas

PhD
  • Speciality: Adjuvants and Formulation Section, Laboratory of Adjuvant and Antigen Research, US Military HIV Research Program,
  • Company: Walter Reed Army Institute of Research
  • Designation: Chief

Personal Information

Dr. Gary Matyas received his Ph.D. in biology from Purdue University and completed his postdoctoral studies at the National Institute Neurological, Communicative Disorders and Stroke at the National Institutes of Health. His postdoctoral research and his Ph.D. studies were centered on the biochemistry and function of glycolipids. In 1988, Dr. Matyas joined the Walter Reed Army Institute of Research as a research chemist in the Department of Membrane Biochemistry, Division of Biochemistry, which later merged with US Military HIV Research Program.

The focus of his research was on vaccines for various infectious diseases, using liposome adjuvants and transcutaneous immunization. He has studied liposomes as adjuvants for vaccines, including HIV, malaria, Campylobacter and COVID-19. He oversees the cGMP manufacture of Army Liposome Formulations (ALF) including ALF43 and ALFQ. Dr. Matyas’ research efforts focus on the development of adjuvants for HIV vaccines. He is the principal investigator for a comparative adjuvant phase 1 clinical trial that studies the effect of various adjuvants on DNA immunization and HIV-1 envelope protein boosts. The trial is being conducted in Kenya. Dr. Matyas has participated in multiple clinical trials with ALF and ALFQ for HIV, malaria, Campylobacter and COVID-19. In July 2012, Dr. Matyas was awarded the Avant-Garde Award for Medications Development from the NIH National Institute on Drug Abuse to develop a combination heroin/HIV vaccine. As part of this award and extended research, Dr. Matyas has developed an ALF-based vaccines that blocks the biological effects of opioids such as heroin and fentanyl. His heroin vaccine has proven effective in preventing overdose in animal studies and is funded for a phase 1 clinical trial.

Scientia Meetings

Connecting Minds for Scientific Progress!

Join us in revolutionizing conferences! Scientia Meetings is launching events across the country, offering a unique platform for scientists and researchers to share knowledge, explore innovative ideas, and foster collaborations. Buy Ticket
Clients

Our Official
Sponsors

Our curated gatherings ensure purposeful networking, creating opportunities tailored to your needs. Let's shape the future together—where knowledge connects, opportunities arise, and science thrives!
Buy Ticket
Get The Latest Updates

Signup For Newsletter

If You Want to Update For on Our Site a#Subscribe Now.